The superiority of radiotherapy for treating Stage 2A testicular seminoma has been confirmed by a new study. Radiation should now be recommended to avoid present uncertainties—under which chemot
TURIN, Italy—All patients with Stage IIA testicular seminoma should be treated with radiotherapy rather than multi-agent chemotherapy according to conclusions from a study reported at the 2016 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO). Abstract: OC-0539
“The bottom line results were that in IIA patients radiotherapy did seem to be a better treatment option as far as overall survival was concerned,” said Scott M Glaser MD, a radiation oncology resident, at the University of Pittsburg Cancer Institute, in Pittsburgh, PA, who reported his group’s findings—with a median follow up of just over five years—from the US National Cancer Database which includes records of 70 percent of all newly diagnosed cancers in the USA.